Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.68
ALKS's Cash-to-Debt is ranked lower than
74% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. ALKS: 1.68 )
Ranked among companies with meaningful Cash-to-Debt only.
ALKS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 1.53 Max: No Debt
Current: 1.68
Equity-to-Asset 0.69
ALKS's Equity-to-Asset is ranked higher than
53% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALKS: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
ALKS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.15  Med: 0.66 Max: 0.97
Current: 0.69
-0.15
0.97
Debt-to-Equity 0.24
ALKS's Debt-to-Equity is ranked higher than
54% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. ALKS: 0.24 )
Ranked among companies with meaningful Debt-to-Equity only.
ALKS' s Debt-to-Equity Range Over the Past 10 Years
Min: -34.56  Med: 0.28 Max: 67.51
Current: 0.24
-34.56
67.51
Debt-to-EBITDA -2.91
ALKS's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. ALKS: -2.91 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ALKS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -11.58  Med: 0.49 Max: 3.94
Current: -2.91
-11.58
3.94
Piotroski F-Score: 4
Altman Z-Score: 8.49
Beneish M-Score: -2.82
WACC vs ROIC
14.14%
-19.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -24.87
ALKS's Operating Margin % is ranked higher than
62% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. ALKS: -24.87 )
Ranked among companies with meaningful Operating Margin % only.
ALKS' s Operating Margin % Range Over the Past 10 Years
Min: -35.7  Med: -18.36 Max: 41.29
Current: -24.87
-35.7
41.29
Net Margin % -24.33
ALKS's Net Margin % is ranked higher than
62% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. ALKS: -24.33 )
Ranked among companies with meaningful Net Margin % only.
ALKS' s Net Margin % Range Over the Past 10 Years
Min: -36.15  Med: -13.55 Max: 69.37
Current: -24.33
-36.15
69.37
ROE % -16.09
ALKS's ROE % is ranked higher than
65% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. ALKS: -16.09 )
Ranked among companies with meaningful ROE % only.
ALKS' s ROE % Range Over the Past 10 Years
Min: -18.25  Med: -5.96 Max: 65.64
Current: -16.09
-18.25
65.64
ROA % -11.27
ALKS's ROA % is ranked higher than
67% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ALKS: -11.27 )
Ranked among companies with meaningful ROA % only.
ALKS' s ROA % Range Over the Past 10 Years
Min: -12.04  Med: -4.55 Max: 27.26
Current: -11.27
-12.04
27.26
ROC (Joel Greenblatt) % -55.54
ALKS's ROC (Joel Greenblatt) % is ranked higher than
67% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. ALKS: -55.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALKS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -61.03  Med: -16.97 Max: 131.93
Current: -55.54
-61.03
131.93
3-Year Revenue Growth Rate 5.50
ALKS's 3-Year Revenue Growth Rate is ranked higher than
53% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ALKS: 5.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALKS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -20.2  Med: 9.9 Max: 69.6
Current: 5.5
-20.2
69.6
GuruFocus has detected 1 Warning Sign with Alkermes PLC ALKS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALKS's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ALKS Guru Trades in Q3 2016

George Soros 4,600 sh (New)
PRIMECAP Management 3,153,560 sh (+25.87%)
Ken Fisher 129,607 sh (+5.29%)
Jeff Auxier 26,751 sh (unchged)
Vanguard Health Care Fund 8,603,676 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Pioneer Investments 155,087 sh (-37.76%)
» More
Q4 2016

ALKS Guru Trades in Q4 2016

Steven Cohen 84,400 sh (New)
PRIMECAP Management 6,376,270 sh (+102.19%)
George Soros 7,200 sh (+56.52%)
Vanguard Health Care Fund 8,660,076 sh (+0.66%)
Jeff Auxier 26,751 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Ken Fisher 118,407 sh (-8.64%)
Pioneer Investments 103,137 sh (-33.50%)
» More
Q1 2017

ALKS Guru Trades in Q1 2017

Jim Simons 124,886 sh (New)
Joel Greenblatt 51,566 sh (New)
Steven Cohen 250,200 sh (+196.45%)
PRIMECAP Management 7,856,543 sh (+23.22%)
Vanguard Health Care Fund 8,694,176 sh (+0.39%)
Murray Stahl 25,000 sh (unchged)
George Soros Sold Out
Pioneer Investments Sold Out
Jeff Auxier 26,651 sh (-0.37%)
Ken Fisher 110,407 sh (-6.76%)
» More
Q2 2017

ALKS Guru Trades in Q2 2017

PRIMECAP Management 9,869,291 sh (+25.62%)
Vanguard Health Care Fund 8,694,176 sh (unchged)
Jeff Auxier 26,651 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Ken Fisher 110,212 sh (-0.18%)
Murray Stahl 22,000 sh (-12.00%)
Steven Cohen 96,000 sh (-61.63%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ALKS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Reduce -0.18%$55.9 - $61.66 $ 50.58-13%110,212
Joel Greenblatt 2017-06-30 Sold Out 0.04%$55.9 - $61.66 $ 50.58-13%0
Vanguard Health Care Fund 2017-03-31 Add 0.39%$52.26 - $61.16 $ 50.58-11%8,694,176
Ken Fisher 2017-03-31 Reduce -6.76%$52.26 - $61.16 $ 50.58-11%110,407
Joel Greenblatt 2017-03-31 New Buy0.04%$52.26 - $61.16 $ 50.58-11%51,566
George Soros 2017-03-31 Sold Out 0.01%$52.26 - $61.16 $ 50.58-11%0
Vanguard Health Care Fund 2016-12-31 Add 0.66%0.01%$42.3 - $59.5 $ 50.58-5%8,660,076
Ken Fisher 2016-12-31 Reduce -8.64%$42.3 - $59.5 $ 50.58-5%118,407
George Soros 2016-12-31 Add 56.52%$42.3 - $59.5 $ 50.58-5%7,200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:HKSE:01177, NAS:SGEN, NAS:EXEL, NAS:JAZZ, NAS:TSRO, NAS:IONS, NAS:BIVV, NAS:BLUE, HKSE:02269, NAS:KITE, NAS:ALNY, NAS:NBIX, NAS:UTHR, XAMS:GLPG, NAS:ACAD, NAS:JUNO, NAS:TECH, XKRX:128940, NAS:PBYI, OSTO:SOBI » details
Traded in other countries:8AK.Germany,
Headquarter Location:Ireland
Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.

Alkermes is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Top Ranked Articles about Alkermes PLC

What Markets Are Really Looking for in Alkermes' Schizophrenia Drug The fate of the drug rests on the results of a phase 3 study
On June 30, Alkermes PLC (NASDAQ:ALKS) released data from a phase 3 study of one of its lead development assets, a drug called ALKS 3831. This study is the first of two phase 3 investigations designed to underpin an application with the U.S. Food and Drug Administration seeking regulatory approval for this drug in a target indication of schizophrenia. If approved, there is a large potential market waiting for the drug when it hits shelves. Ahead of any approval, however, there are a number of points against which it must perform. Read more...
Who Is Winning the Fight Against Opioid Abuse? A recent survey found approximately 23.5 million Americans are addicted to drugs and alcohol
The extent of the opioid epidemic in the U.S. is so pervasive that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) National Survey on Drug Use and Health estimated that around 23.5 million Americans, aged 12 or older, are addicted to drugs and alcohol. Read more...
Naltrexone Showing More Potential in Drug Addiction Treatment Market Teva Pharmaceuticals and Alkermes produce 2 main forms of treatment
In the on-going debate of which drug addiction treatment is more effective, naltrexone is showing more potential than buprenorphine, according to the latest study by researchers from Columbia University. Read more...
BioCorRx Receives New Funding for Opioid Drug 21st Century Cures Act promises $1 billion in research funding
The signing last month of the 21st Century Cures Act into law by President Barack Obama signals a major revamp in the treatment of opioid addiction because of the promise of $1 billion in research funding, as well as a system to hasten approval of drugs and medicine devices by the Food and Drug Administration. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 114.94
ALKS's Forward PE Ratio is ranked lower than
90% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. ALKS: 114.94 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 6.46
ALKS's PB Ratio is ranked lower than
68% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ALKS: 6.46 )
Ranked among companies with meaningful PB Ratio only.
ALKS' s PB Ratio Range Over the Past 10 Years
Min: 1.66  Med: 4.2 Max: 9.25
Current: 6.46
1.66
9.25
PS Ratio 9.59
ALKS's PS Ratio is ranked higher than
55% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. ALKS: 9.59 )
Ranked among companies with meaningful PS Ratio only.
ALKS' s PS Ratio Range Over the Past 10 Years
Min: 2.19  Med: 7.1 Max: 18.85
Current: 9.59
2.19
18.85
EV-to-EBIT -39.08
ALKS's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. ALKS: -39.08 )
Ranked among companies with meaningful EV-to-EBIT only.
ALKS' s EV-to-EBIT Range Over the Past 10 Years
Min: -17501.7  Med: -24.4 Max: 436.6
Current: -39.08
-17501.7
436.6
EV-to-EBITDA -77.95
ALKS's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. ALKS: -77.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALKS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1362.6  Med: 4.7 Max: 262.1
Current: -77.95
-1362.6
262.1
EV-to-Revenue 9.42
ALKS's EV-to-Revenue is ranked higher than
58% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. ALKS: 9.42 )
Ranked among companies with meaningful EV-to-Revenue only.
ALKS' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.4  Med: 6.7 Max: 18.7
Current: 9.42
1.4
18.7
Current Ratio 3.54
ALKS's Current Ratio is ranked lower than
56% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ALKS: 3.54 )
Ranked among companies with meaningful Current Ratio only.
ALKS' s Current Ratio Range Over the Past 10 Years
Min: 2.01  Med: 6.2 Max: 35.69
Current: 3.54
2.01
35.69
Quick Ratio 3.20
ALKS's Quick Ratio is ranked lower than
56% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. ALKS: 3.20 )
Ranked among companies with meaningful Quick Ratio only.
ALKS' s Quick Ratio Range Over the Past 10 Years
Min: 1.95  Med: 5.94 Max: 35.69
Current: 3.2
1.95
35.69
Days Inventory 149.33
ALKS's Days Inventory is ranked lower than
55% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. ALKS: 149.33 )
Ranked among companies with meaningful Days Inventory only.
ALKS' s Days Inventory Range Over the Past 10 Years
Min: 86.09  Med: 128.98 Max: 166.33
Current: 149.33
86.09
166.33
Days Sales Outstanding 90.62
ALKS's Days Sales Outstanding is ranked lower than
67% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. ALKS: 90.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALKS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.46  Med: 82.14 Max: 93.54
Current: 90.62
27.46
93.54
Days Payable 132.52
ALKS's Days Payable is ranked higher than
75% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. ALKS: 132.52 )
Ranked among companies with meaningful Days Payable only.
ALKS' s Days Payable Range Over the Past 10 Years
Min: 39.15  Med: 65.98 Max: 127.84
Current: 132.52
39.15
127.84

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
ALKS's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ALKS: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALKS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.1  Med: -10.2 Max: 2.1
Current: -4.5
-16.1
2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 29.24
ALKS's Price-to-Net-Current-Asset-Value is ranked lower than
86% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. ALKS: 29.24 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALKS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.18  Med: 7.3 Max: 343
Current: 29.24
2.18
343
Price-to-Tangible-Book 9.46
ALKS's Price-to-Tangible-Book is ranked lower than
73% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. ALKS: 9.46 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALKS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.24  Med: 7.7 Max: 365.22
Current: 9.46
1.24
365.22
Price-to-Intrinsic-Value-Projected-FCF 9.80
ALKS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
73% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. ALKS: 9.80 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALKS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2  Med: 4.15 Max: 20.95
Current: 9.8
2
20.95
Price-to-Median-PS-Value 1.35
ALKS's Price-to-Median-PS-Value is ranked lower than
70% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ALKS: 1.35 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALKS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 1.57 Max: 14.5
Current: 1.35
0.38
14.5
Earnings Yield (Greenblatt) % -2.56
ALKS's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. ALKS: -2.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALKS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -6  Med: -0.6 Max: 53.4
Current: -2.56
-6
53.4

More Statistics

Revenue (TTM) (Mil) $804.37
EPS (TTM) $ -1.28
Beta2.31
Short Percentage of Float8.81%
52-Week Range $42.75 - 63.40
Shares Outstanding (Mil)153.66

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 902 1,079 1,361
EPS ($) -0.01 0.44 1.70
EPS without NRI ($) -0.01 0.44 1.70
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}